
MicroPort Scientific Corp.
0853.HKHKSEHealthcareMedical - Devices
最新資料
HK$6.29
−HK$0.30 · -4.55%
0853.HK公司概覽
盤中時間採用HKT。市場資料可能有所延遲。
公司概況
公司網站MicroPort Scientific Corp. is an investment holding company, which engages in the research and development, manufacture, and distribution of medical devices. It operates through the following segments: Cardiovascular Devices Business, Orthopedics Devices Business, Cardiac Rhythm Management Business, Endovascular and Peripheral Vascular Devices Business, Neurovascular Devices Business, Surgical Devices Business, Heart Valve Business, Surgical Robot Devices Business, and Others. The Cardiovascular Devices Business segment offers integrated medical solutions for the treatment of coronary artery-related diseases, develops, manufactures, and commercializes coronary stents and related delivery systems, along with balloon catheters, passive accessories and active devices, in fulfilling the overall demands of doctors and patients worldwide. The Orthopedics Devices Business segment is involved in the total solutions for the treatment of orthopedic problems, with an extensive range of orthopedics products that include reconstructive joints, spine and trauma products, and other professional implants and instruments. The Cardiac Rhythm Management Business segment develops, manufactures, and markets of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure, with products covering pacemakers, defibrillators, and cardiac resynchronization therapy devices. The Endovascular and Peripheral Vascular Devices Business segment focuses on providing integrated disease solutions for aortic and peripheral vascular diseases such as thoracic and abdominal aortic aneurysm, aortic dissection, atherosclerosis, and lower extremity arteriosclerotic occlusion. The Neurovascular Devices Business segment specializes in providing total solutions for the treatment of neurovascular diseases, including hemorrhagic stroke, cerebral atherosclerotic stenosis, and acute ischemic stroke, continuously focused on research and development, production and commercialization of neurovascular therapeutic and access devices. The Surgical Devices Business segment provides overall solutions for cardiac surgery and emergency life support. The Heart Valve Business segment includes sale, manufacture, research, and development of heart valve devices. The Surgical Robot Devices Business segment designs, develops, and commercializes innovative surgical robots. The company was founded by Zhao Hua Chang in 1998 and is headquartered in Shanghai, China.
- 產業
- Medical - Devices
- 部門
- Healthcare
- 總部
- CN
- 執行長
- Jonathan W. Chen
- 上市以來
- 2010年9月24日
- 僱員
- 6,547
市場位置
日內區間
目前HK$6.29,
52週區間
目前HK$6.29,
- 開盤價
- HK$6.505
- 前收盤價
- HK$6.59
- 成交量
- 946.57萬
- 0.76× 平均值
- 平均成交量
- 1246.91萬
- 日均成交量
- 市值
- 120.31億 HKD
- 貝塔
- 0.36
- 市場參考 1
- 50天平均值
- HK$6.6843
- 低於平均水平-5.90%
- 200天平均值
- HK$9.2479
- 低於平均水平-31.98%
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 35.21億 USD
- 本益比(TTM)
- 32.33×
- 股價淨值比(TTM)
- 1.35×
- 股價營收比(TTM)
- 1.54×
- EV/EBITDA
- 39.63×
- 盈餘收益率
- 1.87%
- 自由現金流收益率
- -2.99%
- 股息率
- 0.00%
獲利能力和效率
- 毛利率
- 55.18%
- 營業利益率
- -3.73%
- 淨利潤率
- 4.89%
- 股東權益報酬率
- 4.95%
- 資產報酬率
- 1.31%
- 投入資本報酬率
- -1.65%
財務健康
- 負債權益比
- 1.63×
- 流動比率
- 1.45×
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 9.96億 USD | 10.31億 USD | 9.51億 USD | 8.41億 USD | 7.79億 USD |
| 銷貨成本 | 4.42億 USD | 4.57億 USD | 4.19億 USD | 3.39億 USD | 2.87億 USD |
| 毛利 | 5.54億 USD | 5.74億 USD | 5.32億 USD | 5.02億 USD | 4.92億 USD |
| 研究與開發 | 1.36億 USD | 2.17億 USD | 3.79億 USD | 4.31億 USD | 2.98億 USD |
| 銷售、一般及管理費用 | 4.66億 USD | 4.85億 USD | 5.41億 USD | 5.76億 USD | 5.6億 USD |
| 營業費用 | 6.08億 USD | 7.03億 USD | 10.48億 USD | 10.09億 USD | 8.31億 USD |
| 利息收入 | 1459.86萬 USD | 2274.8萬 USD | 2939.6萬 USD | 1910.7萬 USD | 1582.5萬 USD |
| 利息支出 | 1.11億 USD | 1.02億 USD | 9273.2萬 USD | 7391.2萬 USD | 4271萬 USD |
| 折舊和攤銷 | 1.42億 USD | 9343.3萬 USD | 1.51億 USD | 7630.7萬 USD | 5746.1萬 USD |
| 營業利益 | −5294.92萬 USD | −1.29億 USD | −5.16億 USD | −5.07億 USD | −2.94億 USD |
| 淨利 | 4859.08萬 USD | −2.14億 USD | −4.78億 USD | −4.37億 USD | −2.76億 USD |
公司資料更新於 2026年8月24日。
財報歷史與展望
- 最新每股收益結果
- 0.39
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
0853.HK同業公司
持有0853.HK的ETF
報告持有此股票曝險的交易所交易基金。
Vanguard Total International Stock ETFVXUS1345.24萬0.00%6462億 USD0.05%US$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO1337.12萬0.01%1623億 USD0.06%US$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG966萬0.01%1600.01億 USD0.09%US$81.57+0.64%
Vanguard FTSE All-World ex-US ETFVEU210.01萬0.00%959億 USD0.04%US$85.69+0.82%
iShares Core MSCI Total International Stock ETFIXUS149.86萬0.00%609.08億 USD0.07%US$97.945+0.76%
Schwab Emerging Markets Equity ETFSCHE114.19萬0.01%128.93億 USD0.06%US$36.97+0.71%
State Street SPDR Portfolio Emerging Markets ETFSPEM82.43萬0.00%175.73億 USD0.07%US$52.38+0.61%
Vanguard Total World Stock ETFVT77.48萬0.00%979億 USD0.06%US$160.77+0.53%
Vanguard Total International Stock ETFVXUS- 市場價值
- 1345.24萬
- 重量
- 0.00%
- AUM
- 6462億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$87.71+0.78%
Vanguard FTSE Emerging Markets ETFVWO- 市場價值
- 1337.12萬
- 重量
- 0.01%
- AUM
- 1623億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$60.45+0.72%
iShares Core MSCI Emerging Markets ETFIEMG- 市場價值
- 966萬
- 重量
- 0.01%
- AUM
- 1600.01億 USD
- 費用率
- 0.09%
- 價格 / 1日
- US$81.57+0.64%
Vanguard FTSE All-World ex-US ETFVEU- 市場價值
- 210.01萬
- 重量
- 0.00%
- AUM
- 959億 USD
- 費用率
- 0.04%
- 價格 / 1日
- US$85.69+0.82%
iShares Core MSCI Total International Stock ETFIXUS- 市場價值
- 149.86萬
- 重量
- 0.00%
- AUM
- 609.08億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$97.945+0.76%
Schwab Emerging Markets Equity ETFSCHE- 市場價值
- 114.19萬
- 重量
- 0.01%
- AUM
- 128.93億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$36.97+0.71%
State Street SPDR Portfolio Emerging Markets ETFSPEM- 市場價值
- 82.43萬
- 重量
- 0.00%
- AUM
- 175.73億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$52.38+0.61%
Vanguard Total World Stock ETFVT- 市場價值
- 77.48萬
- 重量
- 0.00%
- AUM
- 979億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$160.77+0.53%
繼續GoAI的研究
在 GoAI 中研究0853.HKresearch.disclaimer





